12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Epanova: Phase III data

The double-blind, U.S. Phase III ESPRIT trial in 647 patients with fasting triglyceride levels of 200-500 mg/dL showed that once-daily 2 and 4 g doses of Epanova as an add-on to statin therapy each met the primary endpoint of reducing non-HDL-C from baseline to week 6 vs. control (4 g olive oil) (4% and 7%, respectively, vs. 1%,...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >